Connect with us


Trends in Femtech Apps: What to Expect in 2024-2025



The femtech market, valued at USD 6.69 billion in 2023 and projected to reach USD 20.59 billion by 2030, addresses women’s health needs through digital solutions. The COVID-19 pandemic, which saw disruptions in healthcare access and economic conditions, heightened the demand for innovations, including fertility trackers, apps with health kit integration, and telemedicine services, which address the health risks and challenges associated with the pandemic’s impact on healthcare accessibility and economic stability. As a result, Femtech has emerged as a critical industry, offering tailored solutions to support women’s health and well-being in the face of evolving global health challenges. In this post, we’ll go over five major trends poised to shape the evolving femtech industry and how they contribute to better well-being for women.

1. The Integration of Mental Support for Postpartum Depression & Women with Menopause

Applications and online tools focused on providing mental health support for postpartum depression and women entering menopause are increasingly on the rise. For postpartum mental health, these apps mostly rely on internet-delivered preventive care through psychoeducation, self-monitoring, and peer support, as well as the use of wearables to monitor biometric data associated with mental health. For instance, internet-based therapy allows postpartum mothers to learn about their unique mental health conditions, circumvent long in-office waiting times by receiving care over virtual meetings, and find support in like-minded communities. Wearable technologies help mental health clinicians, who traditionally rely on subjective and biased self-reports for diagnosis and treatment, to collect information about a patient’s behavior and biological function outside of their appointments, thus assisting them in making more accurate diagnoses, treatment monitoring, and prevention. Likewise, for women in menopause, there’s a growing focus on digital assistance and virtual care, with many applications integrating digital trackers and wearables to assist women in understanding their hormones, body, and health at each stage, as well as virtual care apps that connect users with professionals who provide patients with personalized treatments.

2. Advancing Reproductive Health Solutions in Femtech Apps

The market for reproductive and fertility apps is witnessing significant growth due to the increasing adoption and awareness of digital health technologies among women. With over 74 million women experiencing unintended pregnancies, which lead to over 47,000 deaths annually, reproductive health solutions play a crucial role in empowering women to track their menstrual cycles and plan motherhood effectively. These apps offer personalized reproductive insights, including premenstrual syndrome cycles, ovulation cycles, and likelihood of pregnancy, by recording various indicators, such as past periods, sleep patterns, basal body temperature, cervical fluid details, mood, and sexual activity.

3. Growing Number of Community-Centric Platforms

Female well-being is an ongoing battle. In the real world, women’s needs are often neglected and stigmatized, so those who speak up about their struggles often find themselves ignored or attacked. To provide women with a safe space to connect, share, and find support, more femtech apps are actively incorporating forums, peer support networks, and group activities that foster a supportive virtual community. These platforms help build a sense of belonging and provide a source of support as users freely connect to share experiences and discover new insights about their health. For example, the Peanut App, an online community and social networking platform, connects women at various stages of life, including those planning pregnancy, pregnant women, new mothers, and women experiencing menopause.

4. Incorporating Blockchain Solutions for Electronic Health Records

Blockchain technology is becoming a cornerstone in the femtech industry for several reasons. Firstly, it provides unparalleled security for sensitive health data. By utilizing blockchain, femtech apps can encrypt and store information like fertility data, menstrual cycles, and health records in a way that’s virtually impenetrable to unauthorized access. Furthermore, this technology empowers users with greater control over their health data. Through cryptographic keys, patients can manage who has access to their electronic health records, granting or revoking permissions as needed. This puts users in the driver’s seat when it comes to their own healthcare information, ensuring that only authorized individuals view or modify their data. How is it able to secure patient data? This has to do with blockchain fundamentals. Each block in the blockchain is encrypted and linked to the previous one, forming a chain of blocks. This cryptographic hashing ensures that once data is recorded, it cannot be altered without the consensus of network participants, making the blockchain highly resistant to tampering.

5. The Integration of AI for Health Predictions

Femtech apps are expected to leverage AI algorithms for early illness detection and preventive care. These generative AI technologies, including machine learning and natural language processing, empower health organizations to develop predictive models, analyze medical data, and support their decision-making processes when administering treatments. To work, these algorithms analyze data from wearable devices and mobile apps and make predictions on ovulation cycles, menstrual cycles, fertility, and other health indicators. Beyond fertility, AI in femtech is also used to analyze genetic data, medical histories, lifestyle, and other factors to develop personalized diagnoses and treatments for women’s health conditions, as well as early detection signals to promote preventive care and overall health.


To sum up, the femtech app industry in 2024 and 2025 is seeing some major trends. These include mental health support for postpartum depression and menopausal women, the increasing use of reproductive and fertility apps, and a strong focus on community features. Additionally, there’s a push to safeguard patient records using blockchain technology and the incorporation of AI for health predictions. While no one can say for sure what the future holds, keeping up with these trends will surely help your organization succeed as the industry keeps growing.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Singapore-based fertility centre sets up grant for couples struggling to conceive

This grant aims to support eligible Singaporean couples facing financial and family planning challenges



A Singapore-based fertility centre is to set up a grant to support couples struggling to conceive.

Virtus Fertility Centre Singapore (VFCS) announced that it would set up a grant to support aspiring parents on their IVF journey.

The initial grant is set for at $50,000 SGD and, depending on the take-up rate over the next 12 fiscal months, VFCS plans to increase the pool to benefit more couples in the subsequent years.

The grant will cover the main costs associated with IVF treatments and procedures, including embryo retrieval and transfer, laboratory services and embryo prep. It will also be applicable to fresh and frozen egg transfers.

As grant recipients, their samples will similarly be given a radio frequency identification (RFID) tag, a service VFCS provides for all its patients. It locks the patient’s identity with the respective sample. The RFID identifies gametes—eggs, sperms, or embryos—at every stage of the IVF treatment.

According to VFCS, the grant will also include access to counselling services and wellness resources.

“I’ve witnessed firsthand the emotional toll and occasional frustration that infertility can take on individuals and couples, especially for some who are still young and healthy,” said Dr Roland Chieng, medical director at VFCS.

“The common deterrent of going for fertility treatment is always associated with the cost, more so in a private care setting where their only source of funds is through Medisave.

“By alleviating their financial concerns, we hope ReadyBaby Fertility Grant empowers patients to approach their IVF journey, focusing on their clinical needs and working towards a healthy pregnancy and less on financials.

“With access to the necessary treatments and support, patients can embark on their path to parenthood with renewed confidence, knowing they have the clinical resources and guidance they need to navigate this journey,” he added.

Tim Kwan, VFCS’s managing director, said: “We believe every couple deserves the opportunity to experience the profound joy of parenthood.

“With the ReadyBaby Fertility Grant, we aim to support aspiring couples on their IVF journey and help them bring new life into the world.”

To be eligible for the grant, applicants must be married Singaporean couples diagnosed with medical infertility by a fertility specialist and first-time parents who have not tried IVF before.

To receive the Femtech World newsletter, sign up here.

Continue Reading


Canadian insurer launches partnership to support women’s health

Members of the Canadian insurer Medavie Blue Cross will have access to a dedicated women’s health platform



Angela Johnson, co-founder and CEO of sanoLiving

The Canadian insurer Medavie Blue Cross (MBC) has partnered with the virtual health platform sanoLiving to support women on their menopause journey.

Currently, more than 10 million Canadian women are navigating menopause, often with little support and misinformation about treatments.

With sanoMidLife, sanoLiving’s online menopause platform, Medavie Blue Cross members will have access to a national women’s health platform tailored to provide care and services for women going through the menopause.

The service includes personalised assessments, access to clinicians, treatments, educational content, peer support and AI assistance.

“Many women lack support for their menopause transition due to the misunderstandings of what is ‘normal’ and misinformation about treatments,” said Angela Johnson, co-founder and CEO of sanoLiving.

“Women are seeking solutions that allow them to thrive during midlife. We are thrilled about our alliance with Medavie Blue Cross, and our shared commitment to providing access to care that empowers women.”

Anita Swamy, senior vice president operations at Medavie Blue Cross, added: “We’ve heard first-hand from our members about the need for more menopause-related services.

“Our partnership with sanoLiving creates an innovative way to increase access to care for our members as we continue to focus on the support women need to navigate their benefits and provide forward-thinking options to support their health.”

Studies report one in 10 women exit the workforce due to unmanaged symptoms. Early onset of menopause and symptoms before age 45 can elevate the risk of health issues like heart disease, diabetes, dementia and osteoporosis.

With this new service, Medavie Blue Cross and sanoLiving are aiming to open up the conversation around menopause, reduce stigma and work towards giving women the access to the care they need.

To receive the Femtech World newsletter, sign up here.

Continue Reading


US start-up raises US$2.32m to address pelvic health concerns

The Flyte intravaginal device aims to treat stress urinary incontinence and strengthen pelvic floor muscles



The US women’s health start-up Pelvital has raised US$2.32m in funding to address “unanswered” pelvic health issues.

Minnesota-based Pelvital aims to restore pelvic health with its first product Flyte, an FDA-cleared intravaginal treatment for stress urinary incontinence (SUI) and weakened pelvic floor muscles.

The device, originally developed by physicians from the Arctic University of Norway, uses mechanotherapy, a treatment modality that when paired with an active pelvic floor contraction stimulates tissue regeneration and the creation of neuromuscular memory.

The company will use the funding to speed up the commercialisation of Flyte and raise awareness of pelvic health issues.

“Completing this round is an important step in continuing Pelvital’s unwavering dedication to provide women with innovative solutions for pelvic health, including the treatment of SUI,” said Lydia Zeller, president and CEO of Pelvital.

“This funding will play a crucial role in accelerating our commercialisation of Flyte with a strong emphasis on expanding payor coverage and enhancing clinical education and clinician awareness.”

With this final close, Zeller said, Pelvital would welcome new investors including Pier 70 Ventures, Life Science Angels, Tech Coast Angels Orange County, and Blue Pacific Fund.

Preetha Ram, managing partner at Pier 70 Ventures, would join the Pelvital board of directors.

“Joining Pelvital’s board alongside this investment round is truly an honour,” Ram shared.

“Pier 70 and I are thrilled to be part of this transformational opportunity, as Pelvital’s mission aligns beautifully with our dedication to support disruptive technologies that shake up the status quo in healthcare.

“Pelvital’s pioneering work is shaping a future where women’s health receives the attention and innovation it deserves with novel medical devices like Flyte.”

Oscar Moralez, founder and managing partner of Boomerang Ventures who led the investment round, said: “We are thrilled for the successful completion of this round as we aim to tackle the most pressing healthcare challenges.

“Our participation aims to address the chronic underfunding in women’s healthcare. Investing in Flyte, a truly groundbreaking treatment, addresses underserved pelvic health issues like SUI and contributes to raising vital awareness.”

Two published clinical trials have validated Flyte’s safety, efficacy and durability of treatment effect for women with SUI.

Most recently Pelvital published a paper in Therapeutic Advances in Urology, showing that 71 per cent of study participants achieved dry or near dry conditions as evidenced by a reduction in 24-hour pad weight after using Flyte for between two and 12 weeks.

To receive the Femtech World newsletter, sign up here.

Continue Reading


Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.